NewSquare Capital’s Xenetic Biosciences XBIO Stock Holding History

NewSquare Capital’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26	Closed	-$85	–	912
2023 Q2	$85	Hold	26	–	–	﹤0.01%	801
2023 Q1	$106	Hold	26	–	–	﹤0.01%	822
2022 Q4	$74	Buy	+26	New	+$114	﹤0.01%	779

Other funds holding XBIO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NewSquare Capital's XBIO Position: Q3 2023 in Review

NewSquare Capital sold out of Xenetic Biosciences (XBIO) in Q3 2023, closing a stake of 26 shares — an estimated $85 sold.

NewSquare Capital first reported a position in XBIO in Q4 2022 and held it in 3 quarters. The position peaked at $106 in Q1 2023. 7 funds tracked by Wall St. Rank hold XBIO as of Q3 2023.

NewSquare Capital reported no remaining Xenetic Biosciences position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 26 Xenetic Biosciences shares in Q3 2023, an estimated $85.
NewSquare Capital first reported a position in Xenetic Biosciences in Q4 2022 and held it in 3 quarters.
NewSquare Capital's Xenetic Biosciences position peaked at $106 in Q1 2023.
7 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.